Fred Poordad, MD
In this video interview, Fred Poordad, MD, vice president of academic and clinical affairs at Texas Liver Institute, chief of hepatology at University Transplant Center and professor in the Long School of Medicine at The University of Texas Health Science Center at San Antonio, discusses:
- agents he is using in clinical practice;
- the impact of new CDC guidelines recommending screening all adults for HCV at least once in their lifetime;
- how transplanting HCV-positive organs into HCV-negative recipients can be “the right thing to do if done properly” for patients waiting on the organ transplant list;
- deciding whether to treat the hepatitis C of HCV-infected registrants on the liver transplantation list before or after undergoing surgery;
- the effectiveness of telehealth for HCV patients, particularly in the last few months amid the COVID-19 pandemic; and
- the biggest challenges in HCV: identifying and screening those at risk and better educating the population on the risk of HCV to cut the new infection rate.